This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Use of Sulfanilamide in the Treatment of Streptococcic Carriers. Presented by Dr. Archibald Hoyne and Dr. Hays Bailey (by invitation).
Public health control of scarlet fever depends for the most part on the presence or absence of carriers of hemolytic streptococci in the population. In 1934 it was found that among 4,315 patients released from the Municipal Contagious Disease Hospital after having had scarlet fever in eighteen months there were 190 carriers known to be responsible for cases of secondary scarlet fever. Thus, it is apparent that any treatment that would eliminate the carrier state would be a marked advance in the control of the disease.One year ago it was decided to test the efficiency of sulfanilamide because of the reports of its specific action for streptococci. The plan provided for administering the drug to patients with scarlet fever during the last quarter of the four week period of
THEOBALD WH, LEWIS TW. CHICAGO LARYNGOLOGICAL AND OTOLOGICAL SOCIETY. Arch Otolaryngol. 1938;27(2):240–256. doi:10.1001/archotol.1938.00650030249013
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: